|
23 Apr 2019 |
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
|
|
23 Apr 2019 |
Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy
|
|
18 Apr 2019 |
Arrakis Therapeutics Announces $75 Million Series B Financing to Advance a New Class of Small-Molecule Medicines Targeting RNA
|
|
17 Apr 2019 |
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
|
|
17 Apr 2019 |
RNA Therapeutics Startup Panorama Medicine Raises $3.7 Million to Accelerate Drug Discovery Using Genomics and Artificial Intelligence
|
|
17 Apr 2019 |
PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform
|
|
17 Apr 2019 |
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
|
|
15 Apr 2019 |
Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment
|
|
12 Apr 2019 |
Gyroscope Therapeutics merges with Orbit Biomedical creating a leading retinal gene therapy company
|
|
12 Apr 2019 |
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases
|
|
12 Apr 2019 |
Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
|
|
10 Apr 2019 |
Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen
|
|
09 Apr 2019 |
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
|
|
09 Apr 2019 |
Enesi Pharma and University of Oxford Collaborate to Target Plague With a Novel ImplaVax®-enabled Adenovirus-based Solid Dose Vaccine
|
|
09 Apr 2019 |
LEO Pharma and Elektrofi Expand Partnership to Co-Develop New Antibodies with the Aim of Achieving Improvements in Drug Delivery within Dermatology
|
|
08 Apr 2019 |
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
|
|
08 Apr 2019 |
Ascentage Pharma Announces Clinical Collaboration with Junshi Bioscience to Evaluate the Combination of APG-1387 and Toripalimab in Treating Cancers
|
|
08 Apr 2019 |
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
|
|
08 Apr 2019 |
Hope Medicine announced global license agreement with Bayer AG to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor
|
|
08 Apr 2019 |
Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
|
|
08 Apr 2019 |
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
|
|
04 Apr 2019 |
Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
|
|
03 Apr 2019 |
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
|
|
03 Apr 2019 |
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
|
|
03 Apr 2019 |
Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines
|
